Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2014.55.507
Prognostic value of serum nicotinamide phosphoribosyltransferase in patients with bladder cancer
Kui Zhang
; Department of Forensic Pathology West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, People’s Republic of China
Bin Zhou
; Laboratory of Molecular Translational Medicine, West China Institute of Women and Children’s Health, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of China
Peng Zhang
; Department of Urology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
Zhu Zhang
; Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University Chengdu, People’s Republic of China
Peng Chen
; Department of Forensic Biology West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, People’s Republic of China
Yan Pu
; Department of Forensic Biology West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, People’s Republic of China
Yaping Song
; Laboratory of Molecular Translational Medicine, West China Institute of Women and Children’s Health, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of China
Lin Zhang
; Laboratory of Molecular Translational Medicine, West China Institute of Women and Children’s Health, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of China
Sažetak
Aim To analyze the serum nicotinamide phosphoribosyltransferase
(Nampt) level and its prognostic value in bladder
cancer (BC).
Methods The study included 131 patients with transitional
cell BC and 109 healthy controls from the West China
Hospital of Sichuan University in the period between 2007
and 2013. Nampt concentration in serum was measured
by commercial ELISA kits for human Nampt.
Results The serum Nampt protein level in patients with BC
(mean ± standard deviation, 16.02 ± 7.95 ng/mL) was significantly
higher than in the control group (6.46 ± 2.08 ng/
mL) (P < 0.001). Serum Nampt level was an independent
prognostic marker of non-muscle-invasive BC, with a higher
serum Nampt level (>14.74 ng/mL) indicating shorter
recurrence-free survival rate (hazard ratio = 2.85, 95% confidence
interval, 1.01-8.06; P = 0.048).
Conclusion Our results suggest that serum Nampt level
may serve as a biomarker of BC and an independent prognostic
marker of non-muscle-invasive BC.
Ključne riječi
Hrčak ID:
135103
URI
Datum izdavanja:
15.10.2014.
Posjeta: 842 *